BR9914779A - Composto wf27082, processo para sua produção, composição farmacêutica contendo o mesmo, cepa de fundos pertencente ao gênero acremonium, composto tendo atividade inibidora de desacetilase de histona, processo para sua produção, seu método e uso - Google Patents

Composto wf27082, processo para sua produção, composição farmacêutica contendo o mesmo, cepa de fundos pertencente ao gênero acremonium, composto tendo atividade inibidora de desacetilase de histona, processo para sua produção, seu método e uso

Info

Publication number
BR9914779A
BR9914779A BR9914779-3A BR9914779A BR9914779A BR 9914779 A BR9914779 A BR 9914779A BR 9914779 A BR9914779 A BR 9914779A BR 9914779 A BR9914779 A BR 9914779A
Authority
BR
Brazil
Prior art keywords
compound
production
pharmaceutical composition
composition containing
histone deacetylase
Prior art date
Application number
BR9914779-3A
Other languages
English (en)
Inventor
Hiroaki Mori
Kazutoshi Sakamoto
Yasuhisa Tsurumi
Shigehiro Takase
Motohiro Hino
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP6469A external-priority patent/AUPP646998A0/en
Priority claimed from AUPP9257A external-priority patent/AUPP925799A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR9914779A publication Critical patent/BR9914779A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"COMPOSTO WF27082, PROCESSO PARA SUA PRODUçãO, COMPOSIçãO FARMACêUTICA CONTENDO O MESMO, CEPA DE FUNGOS PERTENCENTE AO GêNERO ACREMONIUM, COMPOSTO TENDO ATIVIDADE INIBIDORA DE DESACETILASE DE HISTONA, PROCESSO PARA SUA PRODUçãO, SEU MéTODO E USO". Composto tetrapeptídico cíclico e seu uso. Especialmente, são descritos um composto WF27082, processo para produção do composto através de cultura, num meio nutriente, de uma cepa produtora de WF27082 pertencente ao gênero Acremonium e recuperando-se o composto de um caldo de cultura, uma composição farmacêutica contendo o composto como ingrediente ativo, em associação com um portador ou excipiente farmaceuticamente aceitável, substancialmente atóxico, o composto para uso como medicamento, uso do composto na manufatura de um medicamento para inibir desacetilase de histona, uso do composto na manufatura de um medicamento para tratar ou prevenir distúrbios inflamatórios, diabetes, complicações diabéticas, talassemia homozigota, fibrose, cirrose, leucemia promielocítica aguda (APL), infecções causadas por protozoários, rejeições de transplante de órgãos, doenças auto-imunes, ou tumores, uso de inibidores de desacetilase de histona como agente imunossupressor ou antitumorigênico, e uso de inibidores de desacetilase de histona na manufatura de um medicamento para tratar ou previnir rejeições de transplante de órgãos, doenças auto-imunes ou tumores.
BR9914779-3A 1998-10-13 1999-10-08 Composto wf27082, processo para sua produção, composição farmacêutica contendo o mesmo, cepa de fundos pertencente ao gênero acremonium, composto tendo atividade inibidora de desacetilase de histona, processo para sua produção, seu método e uso BR9914779A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP6469A AUPP646998A0 (en) 1998-10-13 1998-10-13 Novel compound wf27082b substance
AUPP9257A AUPP925799A0 (en) 1999-03-16 1999-03-16 Novel compound WF27082
PCT/JP1999/005597 WO2000021979A2 (en) 1998-10-13 1999-10-08 Cyclic tetrapeptide and their use as histone deacetylase inhibitor

Publications (1)

Publication Number Publication Date
BR9914779A true BR9914779A (pt) 2001-07-03

Family

ID=25645895

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914779-3A BR9914779A (pt) 1998-10-13 1999-10-08 Composto wf27082, processo para sua produção, composição farmacêutica contendo o mesmo, cepa de fundos pertencente ao gênero acremonium, composto tendo atividade inibidora de desacetilase de histona, processo para sua produção, seu método e uso

Country Status (15)

Country Link
US (1) US6656905B1 (pt)
EP (1) EP1123309A2 (pt)
JP (1) JP2002527449A (pt)
KR (1) KR20010080142A (pt)
CN (1) CN1330660A (pt)
BR (1) BR9914779A (pt)
CA (1) CA2346943A1 (pt)
CZ (1) CZ20011342A3 (pt)
HK (1) HK1042308A1 (pt)
HU (1) HUP0103985A2 (pt)
IL (1) IL142531A0 (pt)
PL (1) PL348648A1 (pt)
TR (1) TR200101049T2 (pt)
TW (1) TW536544B (pt)
WO (1) WO2000021979A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005199D0 (en) * 2000-03-04 2000-04-26 Imp College Innovations Ltd Modulation of histone deacetylase
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
US20040087657A1 (en) * 2001-10-16 2004-05-06 Richon Victoria M. Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
WO2003057722A2 (en) * 2001-12-28 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide compound and use thereof
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
CN1646558B (zh) * 2002-02-20 2010-05-12 国立大学法人九州工业大学 组蛋白脱乙酰酶抑制剂
NZ567758A (en) 2002-03-04 2009-07-31 Merck Hdac Res Llc Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA)
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
WO2003075856A2 (en) 2002-03-07 2003-09-18 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
EP1501489A4 (en) * 2002-04-15 2007-11-21 Sloan Kettering Inst Cancer COMBINATION THERAPY FOR THE TREATMENT OF CANCER
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006512318A (ja) * 2002-11-12 2006-04-13 アルコン，インコーポレイテッド 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター
FR2847817B1 (fr) * 2002-11-28 2006-11-10 Centre Nat Rech Scient Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
US8299126B2 (en) * 2003-02-27 2012-10-30 Leonard A. Cohen Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1640380B1 (en) 2003-06-20 2010-03-10 Riken Histone deacetylase inhibitor and process for producing the same
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
EP1663194B1 (en) 2003-08-26 2010-03-31 Merck HDAC Research, LLC Use of SAHA for treating mesothelioma
AU2004270150C1 (en) 2003-08-29 2011-07-14 Merck Hdac Research, Llc Combination methods of treating cancer
JP2008516979A (ja) * 2004-10-14 2008-05-22 リゲル ファーマシューティカルズ インコーポレーティッド Ｉｒｅｓ仲介性翻訳の複素環式阻害剤およびその使用法
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2522395A1 (en) 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
DK2494969T3 (en) 2005-05-13 2015-06-15 Topotarget Uk Ltd Pharmaceutical formulations of the HDAC inhibitors
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
KR20080032188A (ko) 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
AU2006313517B2 (en) 2005-11-10 2013-06-27 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2008029565A1 (fr) 2006-09-05 2008-03-13 Kyushu Institute Of Technology Composé ayant une activité d'inhibition sur l'histone désacétylase et produit pharmaceutique comprenant le composé en tant qu'ingrédient actif
AR067584A1 (es) * 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
MX2010003230A (es) * 2007-09-25 2010-04-07 Topotarget Uk Ltd Metodos para la sintesis de ciertos compuestos de acido hidroxamico.
CA2706750A1 (en) * 2007-11-27 2009-06-04 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
MX2010009642A (es) * 2008-03-07 2010-09-22 Topotarget As Metodos de tratamiento utilizando infusion continua prolongada de belinostat.
WO2009149201A1 (en) * 2008-06-03 2009-12-10 Cedars-Sinai Medical Center Methods of treatment for pulmonary fibrosis
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
PL219569B1 (pl) 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
CN102153622A (zh) * 2010-12-25 2011-08-17 中国水产科学研究院珠江水产研究所 一种免疫增强剂脯氨酸-甘氨酸环四肽（c14h20n4o4）及应用
CN107141335B (zh) * 2017-04-12 2020-10-20 宁波大学 一种环肽化合物及其制备方法和应用
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07196686A (ja) * 1994-01-06 1995-08-01 Takeda Chem Ind Ltd 化合物ｔａｎ−１７４６類、その製造法および用途
AU712801B2 (en) * 1995-09-20 1999-11-18 Merck Sharp & Dohme Corp. Histone deacetylase as target for antiprotozoal agents
GB2309696B (en) * 1996-01-31 2000-02-23 Merck & Co Inc Antiprotozoal cyclic tetrapeptides
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
AUPP505798A0 (en) 1998-08-04 1998-08-27 Fujisawa Pharmaceutical Co., Ltd. Novel compound fr225497 substance

Also Published As

Publication number Publication date
JP2002527449A (ja) 2002-08-27
WO2000021979A2 (en) 2000-04-20
TR200101049T2 (tr) 2002-01-21
PL348648A1 (en) 2002-06-03
US6656905B1 (en) 2003-12-02
CN1330660A (zh) 2002-01-09
IL142531A0 (en) 2002-03-10
HK1042308A1 (zh) 2002-08-09
CA2346943A1 (en) 2000-04-20
KR20010080142A (ko) 2001-08-22
HUP0103985A2 (hu) 2002-02-28
WO2000021979A3 (en) 2000-07-20
TW536544B (en) 2003-06-11
EP1123309A2 (en) 2001-08-16
CZ20011342A3 (cs) 2001-09-12

Similar Documents

Publication Publication Date Title
BR9914779A (pt) Composto wf27082, processo para sua produção, composição farmacêutica contendo o mesmo, cepa de fundos pertencente ao gênero acremonium, composto tendo atividade inibidora de desacetilase de histona, processo para sua produção, seu método e uso
Pesanti et al. Colchicine effects on lysosomal enzyme induction and intracellular degradation in the cultivated macrophage.
KR880004097A (ko) 글리코펩티드 항생물질
Fass et al. In vitro susceptibilities of Aeromonas hydrophila to 32 antimicrobial agents
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
CN101970459A (zh) 抗微生物化合物
KR860002525A (ko) 거 담 약
JP3560653B2 (ja) イツリンａの製造法及び抗深在性真菌症剤
O'Callaghan et al. The formation of metabolites from cephalosporin compounds
ES8302090A1 (es) Un procedimiento para la preparacion del nuevo antibiotico bmo162-af2, obtenido mediante el cultivo de una cepa perte- neciente al genero bacillus.
US5808111A (en) Stable acitretinoid compounds
Timberlake et al. Differential effects of analogs of cycloheximide on protein and RNA synthesis in Achlya
Leberman et al. Susceptibility of pleuropneumonia-like organisms to action of antibiotics: II. Terramycin and neomycin
IE34196B1 (en) Improvements in and relating to pepsin inhibitors
Sebek The synthesis of neomycin-C14 by Streptomyces fradiae
KR940019724A (ko) 약리학적 효과가 있는 아피오크레아 크리소스퍼마로 부터의 활성 펩타이드인 크리소스퍼민, 이의 제조방법 및 용도
Ohno et al. Mechanism of action of CM-55, a synthetic analogue of the antilipogenic antibiotic cerulenin
Kovacic et al. A novel approach to β-lactam chemistry in vivo: electron transfer and oxy radical formation by iminium
Pope Growth inhibition of tubercle bacilli by analogues of biotin
Bradford et al. The action of aureomycin, of polymyxin B, and of streptomycin in experimental murine pertussis
JPH06503084A (ja) 芳香族アルデヒドおよびその誘導体、ならびに皮膚病および関節炎の治療に有用なそれらの医薬学的組成物
JPH07313180A (ja) 新規ポリエン化合物
CN109674777A (zh) 异绿原酸类化合物在制备神经退行性疾病和忧郁症的药物中的应用
JP3490095B2 (ja) 抗生物質ｔｋｒ２６４８及びその製造方法
US3890436A (en) Antibiotic GP-3 and production thereof by cultivation of {i bacillus cereus

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.